SanofiSNYNASDAQ
Loading
EBITDA Margin Over TimeStable
Percentile Rank21
3Y CAGR-6.6%
5Y CAGR-10.7%
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

3Y CAGR
-6.6%/yr
vs +6.7%/yr prior
5Y CAGR
-10.7%/yr
Recent acceleration
Acceleration
-13.3pp
Decelerating
Percentile
P21
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive growthStable
PeriodValueYoY Change
202527.14%+8.9%
202424.91%-9.0%
202327.37%-17.8%
202233.31%+13.1%
202129.45%-38.5%
202047.86%+68.9%
201928.33%+10.1%
201825.73%-3.3%
201726.61%-6.8%
201628.53%-